BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12409331)

  • 21. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.
    Milpied N; Fielding AK; Pearce RM; Ernst P; Goldstone AH
    J Clin Oncol; 1996 Apr; 14(4):1291-6. PubMed ID: 8648386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Labopin M; Frassoni F; Sanz G; Demeocq F; Prentice H; Cahn JY; Barbui T; Meloni G; Schaefer U; Reiffers J; Gorin N
    Bone Marrow Transplant; 1999 Aug; 24(4):389-96. PubMed ID: 10467328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis.
    Fagioli F; Bacigalupo A; Frassoni F; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Clavio M; Vitale V; Sogno G
    Bone Marrow Transplant; 1994 Mar; 13(3):247-52. PubMed ID: 8199567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis.
    Reiffers J; Labopin M; Sanz M; Korbling M; Blaise D; De La Rubia J; Gorin NC
    Bone Marrow Transplant; 2000 Jun; 25(11):1115-9. PubMed ID: 10849522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.
    Rio B; Chevret S; Vigouroux S; Chevallier P; Fürst S; Sirvent A; Bay JO; Socié G; Ceballos P; Huynh A; Cornillon J; Françoise S; Legrand F; Yakoub-Agha I; Michel G; Maillard N; Margueritte G; Maury S; Uzunov M; Bulabois CE; Michallet M; Clement L; Dauriac C; Bilger K; Gluckman E; Ruggeri A; Buzyn A; Nguyen S; Simon T; Milpied N; Rocha V;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):445-53. PubMed ID: 25460357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia.
    Zhao XS; Chen Y; Zhao XY; Liu DH; Xu LP; Wang Y; Han W; Chen YH; Chen H; Zhang XH; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(6):844-51. PubMed ID: 23992032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.
    Sierra J; Storer B; Hansen JA; Martin PJ; Petersdorf EW; Woolfrey A; Matthews D; Sanders JE; Storb R; Appelbaum FR; Anasetti C
    Bone Marrow Transplant; 2000 Aug; 26(4):397-404. PubMed ID: 10982286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Gahrton G; Mandelli F; Carella M; Herve P; Gratwohl A; Goldman J
    Leukemia; 1994 Jun; 8(6):924-8. PubMed ID: 8207985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
    Gratwohl A; Hermans J; Niederwieser D; Frassoni F; Arcese W; Gahrton G; Bandini G; Carreras E; Vernant JP; Bosi A
    Bone Marrow Transplant; 1993 Nov; 12(5):509-16. PubMed ID: 8298562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).
    Gratwohl A; Hermans J
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S7-9. PubMed ID: 8769691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
    Gorin NC; Labopin M; Frassoni F; Milpied N; Attal M; Blaise D; Meloni G; Iori AP; Michallet M; Willemze R; Deconninck E; Harousseau JL; Polge E; Rocha V
    J Clin Oncol; 2008 Jul; 26(19):3183-8. PubMed ID: 18506024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
    Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
    Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
    Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Al-Ali HK; Brand R; van Biezen A; Finke J; Boogaerts M; Fauser AA; Egeler M; Cahn JY; Arnold R; Biersack H; Niederwieser D; de Witte T
    Leukemia; 2007 Sep; 21(9):1945-51. PubMed ID: 17611571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
    Reiffers J; Stoppa AM; Attal M; Michallet M; Marit G; Blaise D; Huguet F; Corront B; Cony-Makhoul P; Gastaut JA; Laurent G; Molina L; Broustet A; Maraninchi D; Pris J; Hollard D; Faberes C
    Leukemia; 1996 Dec; 10(12):1874-82. PubMed ID: 8946925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).
    Oosterveld M; Suciu S; Verhoef G; Labar B; Belhabri A; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Zittoun R; Hess U; Anak O; Beeldens F; Willemze R; de Witte T
    Leukemia; 2003 May; 17(5):859-68. PubMed ID: 12750698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.